QIAGEN N.V.

QIAGEN N.V. (QGEN) is a publicly traded US company. Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

The company reports trailing twelve-month revenue of $2.09B and net income of $424.88M.

Key metrics include a return on equity of 11.3%.

Investors tracking QGEN can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.